All’s well that ends well
Biotechs across all market cap tiers gained in 4Q19, recovering from 3Q losses
Biotech companies across all market cap tiers posted big gains in the fourth quarter of 2019, with median changes ranging from 7-18%. 4Q19 growth was enough to erase prior quarter losses, putting all tiers in the black for the full year.
All companies with starting valuations over $10 billion were up in 4Q19, gaining a median of 13% in 4Q19 and 10% in 2019 overall. The group added $105.3 billion in total value in the quarter. The biggest move was 35% by Regeneron Pharmaceuticals Inc. (NASDAQ:REGN), which gained steadily throughout the quarter, posting its highest volume on Nov. 5 after reporting 3Q19 earnings above estimates, a planned $1 billion share buyback, and positive interim Phase III data for Libtayo cemiplimab-rwlc to treat first-line non-small cell lung cancer...